מנבאו - Menveo

× ×ª×× × ×ª×¨××¤×

××¡× ×××¨××××ª

×××¨×©×

×§×××¦× ×¤×¨××§××××××ª (ATC4)

J07AH
Meningococcal vaccines

××¨××× ×¤×¢×× (ATC5)

Meningococcal vaccines group a 10 MCG / 0.5 ML âJ07AH02
Meningococcal vaccines group c 5 MCG / 0.5 ML âJ07AH02
Meningococcal vaccines group w 5 MCG / 0.5 ML âJ07AH02
Meningococcal vaccines group y 5 MCG / 0.5 ML âJ07AH02

×¦××¨×ª ××ª×

×ª×× ×©×¨××¨× - I.M

×¦××¨×ª ××× ××

POWDER AND SOLUTION FOR SOLUTION FOR INJECTION

××ª××××

Menveo is indicated for active immunization of children (2 years of age and above), adolescents and adults up to the age of 55 years, at risk of exposure to Neisseria meningitidis groups A, C, W135 and Y, to prevent invasive disease. The use of this vaccine should be in accordance with official recommendations.

× ×ª×× × ××¡×

×ª××¨×× ××××× ××¡×

21/01/2016

××××××ª ××¡×

×ª×¨××¤× ××××××ª ××¨××©×× ×¢'× ×¨××¤× ××××× ×× ××××× ×××¨×ª

××ª×××× ××¡×

××ª××××	×ª××¨×× ×××××	×ª××× ×§××× ×	Class Effect	××¦× ××××	××¡××¡ ××××××ª
××¡×¨ ×××¢×¨××ª ×××©××× ×××× ××¡×¨ ××¤×§×××¨ D, ×¤×¨××¤×¨×××× ××××¨××× ×××©××× C5-9 ×× C3	21/01/2016
××¡×¤×× ××, ×××¤××¡×¤×× ×× ×× ×××××ª ×× ×ª×¤×§××××ª, × ×¨××©×ª ×× ×××××ª.	21/01/2016

×©××××© ××¡×

××¡××¨×ª ××××× ××¡×

××××¡×× ××× ×ª× ×¢×××¨ ×××× ××××§× ×××× ××××:

1. ××¡×¤×× ××, ×××¤××¡×¤×× ×× ×× ×××××ª ×× ×ª×¤×§××××ª, × ×¨××©×ª ×× ×××××ª.

2. ××¡×¨ ×××¢×¨××ª ×××©××× ×××× ××¡×¨ ××¤×§×××¨ D, ×¤×¨××¤×¨×××× ××××¨××× ×××©××× C5-9 ×× C3

×¢××× ××¨××¤× ×××××¨××ª ××¢×××

×¢××× ××¦×¨××	Â

×¢×¨××× ×××××§××¨×¤×××	×¢×¨××× ×§×©××¨×× ×××××§××¨×¤×××
×× ××× ×××××¨ ××©×¨× ×××¨××××ª

×××¤××© ××××¨××	××××¨×× ×-PubMed
××××¢ ××¨×©×ª	RxList WebMD Drugs.com
×©× ××¦×¨×	GLAXO SMITHKLINE VACCINES S.R.L., ITALY
×©× ××¢× ××¨××©××	GLAXO SMITH KLINE (ISRAEL) LTD
×¨××©×××	×ª××¨×× ×××©×: 03/2011. ×¨××©××× ××ª××¨××: 08/2017
×ª××¨×× ×¢×××× ×××¨××	14/02/24